Details:
CAM2029 is a ready-to-use, long-acting subcutaneous depot of octreotide used for the treatment of autosomal dominant polycystic liver disease. CAM2029 is developed for enhanced octreotide exposure and easy self-administration by patients using a prefilled pen injector.
Lead Product(s): Octreotide Acetate
Therapeutic Area: Genetic Disease Product Name: CAM2029
Highest Development Status: Phase II Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2021